Molecular Pathology of Breast Cancer What a Pathologist Needs to Know
Molecular Pathology of Breast Cancer What a Pathologist Needs to Know
复制标题
DOI：
10.1309/ajcpiv9iq1mrqmoo
复制
发表时间：
2012-12-01
影响因子：
3.5
通讯作者：
Allison, Kimberly H.
中科院分区：
文献类型：
--
作者：
Allison, Kimberly H.
病理学家现在比以往任何时候都更“诊断肿瘤学家”，并作为疾病生物学的临床顾问发挥关键作用。在过去的15年中，分子信息改变了我们对乳腺癌生物多样性的认识，并改变了临床治疗决策的方式。对乳腺癌的当前分子分类和从前驱体到侵袭性疾病的生物学途径的基本了解是为诊断实践提供信息和担任临床顾问的关键。此外，目前正在乳腺癌组织中使用单一标记物和基于小组的分子测试来预测特定疗法的益处，例如HER2靶向生物疗法和化疗。熟悉当前涉及这些分子检测的问题以及病理学家在确保适当的组织处理、组织选择和结果解释和相关性方面的作用，对于提供最佳的患者护理至关重要。
Pathologists are now more than ever "diagnostic oncologists" and serve a critical role as clinical consultants on the biology of disease. In the last decade and a half molecular information has transformed our thinking about the biologic diversity of breast cancers and redirected the way clinical treatment decisions are made. A basic understanding of the current molecular classification of breast cancers and the biologic pathways from precursors to invasive disease is key to both informing diagnostic practice and serving as clinical consultants. In addition, both single-marker and panel-based molecular tests are currently being utilized in breast cancer tissue to predict the benefit of specific therapies such as HER2-targeted biologic therapy and chemotherapy. Familiarity with the current issues involving these molecular tests as well as the pathologist's role in ensuring appropriate tissue handling, tissue selection, and results interpretation and correlation are paramount to providing optimal patient care.